1 not yet recruiting, 1 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow KMT2A-rearranged: new trials by email Literature Review of KMT2A-rearranged trials Research Report on KMT2A-rearranged
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia Revumenib, Blinatumomab - Blinatumomab, Revumenib | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2026-11-18 | 2026-08-12 |
| Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML Ziftomenib, Mezigdomide - KMT2A-rearranged, NPM1-mutant Refractory or Relapsed AML | Phase 1 | Recruiting | Massachusetts General Hospital | 24 | 2026-09-02 | 2026-10-08 |
Leukemia, Myeloid, Acute (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Leukemia (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Lymphoid (1) · Leukemia, Myeloid (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1)
blinatumomab (1) · revumenib (1)
M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1)
United States (2)
Amir Fathi, MD (1) · Elias J Jabbour, MD (1)